Comparative Pharmacology
Head-to-head clinical analysis: ARYNTA versus DEMEROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARYNTA versus DEMEROL.
ARYNTA vs DEMEROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARYNTA (pembrolizumab) is a humanized monoclonal antibody that binds to the programmed death-1 (PD-1) receptor on T cells, blocking its interaction with PD-L1 and PD-L2, thereby restoring anti-tumor immune responses.
Meperidine is an opioid agonist that binds to mu-opioid receptors in the central nervous system, mimicking endogenous endorphins to produce analgesia, sedation, and euphoria. It also has additional weak actions at kappa and delta receptors.
400 mg orally once daily
50-150 mg IM, IV, or SC every 3-4 hours as needed for pain; oral 50-150 mg every 3-4 hours.
None Documented
None Documented
Terminal elimination half-life is 2-4 hours in healthy adults, prolonged to 6-12 hours in moderate to severe renal impairment (CrCl <30 mL/min).
2.5-4 hours; prolonged in hepatic impairment (7-11 hours) and elderly.
Primarily renal elimination (70-80% unchanged), with 10-15% fecal excretion via biliary secretion.
Renal (90% as metabolites and unchanged drug; ~5% unchanged) and biliary/fecal (minor).
Category C
Category C
Opioid Analgesic
Opioid Analgesic